JP7700039B2 - 抗ｔｃｒ抗体分子およびその使用 - Google Patents

抗ｔｃｒ抗体分子およびその使用 Download PDF

Info

Publication number
JP7700039B2
JP7700039B2 JP2021539095A JP2021539095A JP7700039B2 JP 7700039 B2 JP7700039 B2 JP 7700039B2 JP 2021539095 A JP2021539095 A JP 2021539095A JP 2021539095 A JP2021539095 A JP 2021539095A JP 7700039 B2 JP7700039 B2 JP 7700039B2
Authority
JP
Japan
Prior art keywords
subfamily
cells
cancer
domain
tcrβ
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021539095A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022524692A (ja
JP2022524692A5 (https=
Inventor
レーウ，アンドレアス
アーキンストール，スティーブン
Original Assignee
マレンゴ・セラピューティクス，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マレンゴ・セラピューティクス，インコーポレーテッド filed Critical マレンゴ・セラピューティクス，インコーポレーテッド
Publication of JP2022524692A publication Critical patent/JP2022524692A/ja
Publication of JP2022524692A5 publication Critical patent/JP2022524692A5/ja
Application granted granted Critical
Publication of JP7700039B2 publication Critical patent/JP7700039B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021539095A 2019-01-04 2020-01-03 抗ｔｃｒ抗体分子およびその使用 Active JP7700039B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962788497P 2019-01-04 2019-01-04
US62/788,497 2019-01-04
US201962803893P 2019-02-11 2019-02-11
US62/803,893 2019-02-11
PCT/US2020/012162 WO2020142672A2 (en) 2019-01-04 2020-01-03 Anti-tcr antibody molecules and uses thereof

Publications (3)

Publication Number Publication Date
JP2022524692A JP2022524692A (ja) 2022-05-10
JP2022524692A5 JP2022524692A5 (https=) 2023-03-06
JP7700039B2 true JP7700039B2 (ja) 2025-06-30

Family

ID=71407087

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021539095A Active JP7700039B2 (ja) 2019-01-04 2020-01-03 抗ｔｃｒ抗体分子およびその使用

Country Status (8)

Country Link
US (1) US20220064255A1 (https=)
EP (1) EP3906057A4 (https=)
JP (1) JP7700039B2 (https=)
CN (1) CN113543807A (https=)
AU (2) AU2020204686A1 (https=)
CA (1) CA3125345A1 (https=)
GB (1) GB2595980B (https=)
WO (1) WO2020142672A2 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3548055A4 (en) 2016-12-02 2020-08-19 University of Southern California SYNTHETIC IMMUNE RECEPTORS AND THEIR PROCESSES FOR USE
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
CA3105448A1 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
CN119039441A (zh) 2019-02-21 2024-11-29 马伦戈治疗公司 与nkp30结合的抗体分子及其用途
GB2599228B (en) 2019-02-21 2024-02-07 Marengo Therapeutics Inc Multifunctional molecules that bind to T cell related cancer cells and uses thereof
MX2021010857A (es) 2019-03-11 2021-12-15 Janssen Biotech Inc Anticuerpos biespecificos anti-v(beta17)/anti-cd123.
WO2021097325A1 (en) * 2019-11-14 2021-05-20 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
AU2020416273A1 (en) * 2020-01-03 2022-07-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
MX2023000984A (es) * 2020-07-23 2023-05-03 Dyne Therapeutics Inc Complejos dirigidos al musculo y usos de los mismos para el tratamiento de distrofinopatias.
EP4185320A4 (en) * 2020-07-23 2025-10-08 Dyne Therapeutics Inc MUSCLE TARGETING COMPLEXES AND THEIR USES IN THE TREATMENT OF MUSCLE ATROPHY
CN116194470B (zh) * 2020-07-23 2025-10-03 达因疗法公司 肌肉靶向复合物及其用途
CA3190987A1 (en) * 2020-08-10 2022-02-17 Janssen Biotech, Inc. Materials and methods for producing bioengineered virus specific lymphocytes
TW202227495A (zh) * 2020-09-11 2022-07-16 美商健生生物科技公司 用於調節β鏈介導之免疫的方法及組成物
US20220089737A1 (en) * 2020-09-11 2022-03-24 Janssen Biotech, Inc. Multi-specific immune targeting molecules and uses thereof
WO2022056197A1 (en) 2020-09-11 2022-03-17 Janssen Biotech, Inc. Immune targeting molecules and uses thereof
IL308258A (en) 2021-05-05 2024-01-01 Immatics Biotechnologies Gmbh Bma031 antigen binding polypeptides
CN115820697B (zh) * 2022-09-23 2024-07-30 中国海洋大学 一种免疫细胞及其制备方法和应用
JP2026501572A (ja) * 2022-12-27 2026-01-16 イェール ユニバーシティー Ｔｃｒ－ｖｂｅｔａ特異的治療用分子、及びその使用
CN120435501A (zh) * 2022-12-30 2025-08-05 上药生物治疗（香港）有限公司 细胞原位分泌抗体及其用途
WO2024197082A2 (en) * 2023-03-21 2024-09-26 Marengo Therapeutics, Inc. Tcr targeting molecules and uses thereof
AU2024240821A1 (en) 2023-03-23 2025-11-06 Bodhi Bio Llc Compositions and methods for antigen-specific therapy
EP4704897A1 (en) * 2023-04-27 2026-03-11 Marengo Therapeutics, Inc. Combination therapies using molecules binding to tcr
US20250074966A1 (en) * 2023-08-31 2025-03-06 Adaptive Biotechnologies Corporation Agents and methods for preventing or inhibiting adaptive immune responses associated with multiple sclerosis
WO2025051339A1 (en) * 2023-09-05 2025-03-13 Tiber Biotech Srl SINGLE-CHAIN VARIABLE FRAGMENT AND MOLECULES DERIVING THEREFROM THAT BIND FRAGMENT TRVB5-1 OF THE β CHAIN OF HUMAN T-CELL RECEPTOR
WO2026011097A1 (en) * 2024-07-03 2026-01-08 Yale University Antibody drug conjugates comprising tcr-vbeta specific therapeutic molecules and uses thereof
CN120064640B (zh) * 2025-01-15 2026-01-23 中牧实业股份有限公司 一种猪细小病毒vp2双抗体夹心定量检测试剂盒及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766947A (en) * 1988-12-14 1998-06-16 Astra Ab Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor
JPH0787994A (ja) * 1993-04-30 1995-04-04 Sumitomo Electric Ind Ltd Ｔ細胞抗原受容体Ｖβ２２に対するモノクローナル抗体及びその製造方法
PL328790A1 (en) * 1996-10-04 1999-02-15 Univ Jefferson T-lymphocytes provoking an immunological response and methods of using them
AU2006300951A1 (en) * 2005-10-11 2007-04-19 Domantis Limited Antibody polypeptide library screening and selected antibody polypeptides
US20130273089A1 (en) * 2011-11-03 2013-10-17 Tolera Therapeutics, Inc. Antibody and methods for selective inhibition of t-cell responses
US20170335281A1 (en) * 2014-03-15 2017-11-23 Novartis Ag Treatment of cancer using chimeric antigen receptor
EA035419B9 (ru) * 2014-05-29 2020-08-07 Мэкроудженикс, Инк. Триспецифичные связывающие молекулы и способы их применения
LT3611192T (lt) * 2015-05-13 2025-06-25 Ablynx N.V. T ląstelių rekrutingo polipeptidai tcr alfa/beta reaktyvumo pagrindu
JP2018517712A (ja) * 2015-06-01 2018-07-05 メディジーン イミュノテラピーズ ゲーエムベーハー Ｔ細胞受容体特異的抗体
WO2017040930A2 (en) * 2015-09-03 2017-03-09 The Trustees Of The University Of Pennsylvania Biomarkers predictive of cytokine release syndrome
JP7291396B2 (ja) * 2016-11-22 2023-06-15 ティーシーアール２ セラピューティクス インク． 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
CA3105448A1 (en) * 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHOI, Y. et. al.，A method for production of antibodies to human T-cell receptor beta-chain variable regions，Proceedings of the National Academy of Sciences of the United States of America，1991年，Vol. 88, No. 19，P. 8357-8361，DOI:10.1073/pnas.88.19.8357
MEILLEUR, C. E. et. al.，Bacterial Superantigens Expand and Activate, Rather than Delete or Incapacitate, Preexisting Antigen-Specific Memory CD8+ T Cells，Journal of Infectious Diseases，2018年11月12日，Vol. 219, No. 8，P. 1307-1317，DOI:10.1093/infdis/jiy647

Also Published As

Publication number Publication date
WO2020142672A3 (en) 2020-08-20
CA3125345A1 (en) 2020-07-09
GB2595980A (en) 2021-12-15
GB2595980B (en) 2023-06-14
US20220064255A1 (en) 2022-03-03
JP2022524692A (ja) 2022-05-10
CN113543807A (zh) 2021-10-22
AU2025204695A1 (en) 2025-09-04
AU2020204686A1 (en) 2021-07-22
WO2020142672A2 (en) 2020-07-09
EP3906057A4 (en) 2022-09-14
EP3906057A2 (en) 2021-11-10
GB202109794D0 (en) 2021-08-18

Similar Documents

Publication Publication Date Title
JP7700039B2 (ja) 抗ｔｃｒ抗体分子およびその使用
JP7590430B2 (ja) 抗ｔｃｒ抗体分子およびその使用
US20250034217A1 (en) Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof
JP7033549B2 (ja) 細胞に基づくネオ抗原ワクチンおよびその使用
JP7832892B2 (ja) Ｌｉｌｒｂ１ベースのキメラ抗原受容体
JP6942467B2 (ja) タグ化キメラエフェクター分子およびそのレセプター
JP7824728B2 (ja) 遺伝子操作された細胞を調製するための方法および組成物
US11590167B2 (en) Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors
US20180319862A1 (en) Chimeric receptors containing traf-inducing domains and related compositions and methods
JP2024147697A (ja) 免疫細胞機能の改善
JP2026507388A (ja) 新規ｃｄ１９標的化ポリペプチドおよびｃｄ１９標的免疫療法
RU2795454C2 (ru) Способы и композиции для получения генно-инженерных клеток
US20250092363A1 (en) Placenta-derived allogeneic car-t cells and uses thereof
RU2773159C2 (ru) Химерные рецепторы, содержащие traf-6-индуцирующие домены, и связанные с ними композиции и способы
KR20260013488A (ko) 면역 이펙터 세포 및 이의 용도

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230104

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230222

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240405

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240802

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250203

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250526

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250618

R150 Certificate of patent or registration of utility model

Ref document number: 7700039

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150